Menu
Menu
ABOUT OUR REPORT
ABOUT OUR REPORT
Our story begins way back in 2001 when regional blood services around the country were consolidated and the South African National Blood Service (SANBS) was formed. Today we look back with pride on what we have accomplished by our strong focus on people care and safety, quality, sheer determination and resilience.
It is through the invaluable contributions of our dedicated donors, our heroes that are our staff and our loyal partners that SANBS has triumphed and overcome extreme challenges. We share our pride with you all in our 2022 Integrated Report and look forward to the future as we continue to live up to our purpose of being ‘Trusted to save lives’.
See some of the stories of our recipients receiving YOUR gift of life!
Our story begins way back in 2001 when regional blood services around the country were consolidated and the South African National Blood Service (SANBS) was formed. Today we look back with pride on what we have accomplished by our strong focus on people care and safety, quality, sheer determination and resilience.
It is through the invaluable contributions of our dedicated donors, our heroes that are our staff and our loyal partners that SANBS has triumphed and overcome extreme challenges. We share our pride with you all in our 2022 Integrated Report and look forward to the future as we continue to live up to our purpose of being ‘Trusted to save lives’.
See some of the stories of our recipients receiving YOUR gift of life!
Regional Blood Services around the country come together and SANBS is born. Western Cape Blood Services continue their own and collaborate with SANBS.
South Africa becomes the first country in the world to implement large scale individual donation nucleic acid testing for all blood donation, and screening for the genetic material of HIV and hepatitis B and C viruses. This testing reduced the infectious window period significantly.
As our journey continued, we took a close look at the third most common cause of maternal death in South Africa and launched the “save mother save baby” initiative which was supported through the rollout of emergency blood fridges, and which proactively reached out to and helped obstetric hemorrhage patients.
Our quest to upgrade our testing technology led to the implementation of high-resolution HLA testing using next generation sequencing which allowed us to provide superior results to facilitate hematopoietic stem cell and bone marrow and solid organ transplantation.
This was the year we changed how the world sees us. Our corporate identity was redesigned to reflect our dedication to breathing life into people’s stories - using the red line to represent the lifeline that blood offers, it illustrates how the donor and recipients are linked. SANBS undertook to automate all 83 cross-matching blood banks around the country. Moving from a fully manual process to automation and electronic crossmatch.
SANBS joined a panel of countries on the blood transfusion genomics consortium. We have collaborated with member countries including the USA, UK, Australia and Canada for genotyping research aimed at providing a cost-effective test solution in a blood bank setting. In that same year the award-winning Project Bloodwing was presented as one of SANBS’ flagship innovations - arguably the most efficient way to bring essential services to the outlying areas in emergencies, the drone was introduced to improve service delivery to the constituents.
All the way along our journey we flexed our research muscle and at the dawn of the Covid-19 pandemic, in collaboration with our research partners, we embarked on a groundbreaking convalescent plasma clinical trial in real time for the treatment of Covid-19 patients locally. Continuing the Covid-19 research, SANBS performed 3 cross-sectional seroprevalence studies for the antibodies to SARS-COV-2 enabling the government to make public health decisions.
We introduced serum ferritin testing for whole blood donors to assist in the monitoring of individual donor iron stores. SANBS can alert donors and assist in managing blood iron stores to avoid related medical side effects. Our journey has now brought us to our 21st Birthday but we couldn't have come this far without the unwavering support of our dedicated donors, staff, partners and service providers. We share our pride with you and of course we continue to live up to our purpose: trusted to save lives. Here's to another 21 years of giving the gift of life.
Regional Blood Services around the country come together and SANBS is born. Western Cape Blood Services continue their own and collaborate with SANBS.
South Africa becomes the first country in the world to implement large scale individual donation nucleic acid testing for all blood donation, and screening for the genetic material of HIV and hepatitis B and C viruses. This testing reduced the infectious window period significantly.
As our journey continued, we took a close look at the third most common cause of maternal death in South Africa and launched the “save mother save baby” initiative which was supported through the rollout of emergency blood fridges, and which proactively reached out to and helped obstetric hemorrhage patients.
Our quest to upgrade our testing technology led to the implementation of high-resolution HLA testing using next generation sequencing which allowed us to provide superior results to facilitate hematopoietic stem cell and bone marrow and solid organ transplantation.
This was the year we changed how the world sees us. Our corporate identity was redesigned to reflect our dedication to breathing life into people’s stories - using the red line to represent the lifeline that blood offers, it illustrates how the donor and recipients are linked. SANBS undertook to automate all 83 cross-matching blood banks around the country. Moving from a fully manual process to automation and electronic crossmatch.
SANBS joined a panel of countries on the blood transfusion genomics consortium. We have collaborated with member countries including the USA, UK, Australia and Canada for genotyping research aimed at providing a cost-effective test solution in a blood bank setting. In that same year the award-winning Project Bloodwing was presented as one of SANBS’ flagship innovations - arguably the most efficient way to bring essential services to the outlying areas in emergencies, the drone was introduced to improve service delivery to the constituents.
All the way along our journey we flexed our research muscle and at the dawn of the Covid-19 pandemic, in collaboration with our research partners, we embarked on a groundbreaking convalescent plasma clinical trial in real time for the treatment of Covid-19 patients locally. Continuing the Covid-19 research, SANBS performed 3 cross-sectional seroprevalence studies for the antibodies to SARS-COV-2 enabling the government to make public health decisions.
We introduced serum ferritin testing for whole blood donors to assist in the monitoring of individual donor iron stores. SANBS can alert donors and assist in managing blood iron stores to avoid related medical side effects. Our journey has now brought us to our 21st Birthday but we couldn't have come this far without the unwavering support of our dedicated donors, staff, partners and service providers. We share our pride with you and of course we continue to live up to our purpose: trusted to save lives. Here's to another 21 years of giving the gift of life.
This report is prepared in accordance with the Integrated Reporting Framework of The International Financial Reporting Standards Foundation and provides our stakeholders with a concise and transparent assessment of our ability to achieve our mandate and create sustainable value.
Our integrated report provides our stakeholders (including our employees, regulators and society) with a concise, material and transparent assessment of our governance, strategy and performance for the period 1 April 2021 to 31 March 2022.
Our integrated report is a demonstration of our value creation story. It aims to provide a balanced and accurate reflection of value creation, preservation and erosion in terms of our strategy, performance, risks, opportunities, trade-offs and future outlook in relation to material financial, economic, social and governance issues.
This report primarily addresses how we create value over the short-, medium- and long-term, with a demonstration of the effects on the six capitals (i.e. outcomes) providing our stakeholders with a transparent and holistic view of our business operations.
Material events up to the date of approval have been included and should be read in conjunction with our full set of annual financial statements (AFS) for a comprehensive overview of our financial performance. Review our AFS .
This report is prepared in accordance with the Integrated Reporting Framework of The International Financial Reporting Standards Foundation and provides our stakeholders with a concise and transparent assessment of our ability to achieve our mandate and create sustainable value.
Our integrated report provides our stakeholders (including our employees, regulators and society) with a concise, material and transparent assessment of our governance, strategy and performance for the period 1 April 2021 to 31 March 2022.
Our integrated report is a demonstration of our value creation story. It aims to provide a balanced and accurate reflection of value creation, preservation and erosion in terms of our strategy, performance, risks, opportunities, trade-offs and future outlook in relation to material financial, economic, social and governance issues.
This report primarily addresses how we create value over the short-, medium- and long-term, with a demonstration of the effects on the six capitals (i.e. outcomes) providing our stakeholders with a transparent and holistic view of our business operations.
Material events up to the date of approval have been included and should be read in conjunction with our full set of annual financial statements (AFS) for a comprehensive overview of our financial performance. Review our AFS .
Capital available to us
How we use the capital to create value
Our impact and the value we delivered
Capital available to us
How we use the capital to create value
Our impact and the value we delivered